<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301561</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12110 STRATALL</org_study_id>
    <nct_id>NCT00301561</nct_id>
  </id_info>
  <brief_title>Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL)</brief_title>
  <official_title>Expanded Access to Antiretroviral Therapy in Africa: Assessment of the Patients' Management in District Hospitals With a Simplified Follow-up Approach (ANRS 12110 STRATALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Access to antiretroviral therapy (ART) is still limited in Africa (11% of patients in&#xD;
      immediate need in June 2005). Face to the scope of the need and the constraints&#xD;
      (unavailability and cost of viral load and CD4 cell count, lack of physicians…), WHO has&#xD;
      developed a follow-up approach based on a simplified monitoring. However, this &quot;simplified&quot;&#xD;
      approach which represents a major stake for the expanded access to ART has been little&#xD;
      evaluated against the gold standard approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Justification&#xD;
&#xD;
      Access to antiretroviral therapy (ART) is still limited in Africa (11% of patients in&#xD;
      immediate need in June 2005). Face to the scope of the need and the constraints&#xD;
      (unavailability and cost of viral load and CD4 cell count, lack of physicians…), WHO has&#xD;
      developed a follow-up approach based on a simplified monitoring. This &quot;simplified&quot; approach&#xD;
      restricting the use of complementary exams including biologic criteria of effectiveness and&#xD;
      tolerability, some people consider this approach as dangerous for the patient but also for&#xD;
      the community (rapid emergence of resistances) and that it would be preferable to treat less&#xD;
      patients and only with the gold standard approach. In practice, this &quot;simplified&quot; approach&#xD;
      which represents a major stake for the expanded access to ART has been little evaluated&#xD;
      against the gold standard approach.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      Main objective: To compare the increase in the CD4 cell count in patients receiving ART with&#xD;
      a &quot;simplified&quot; approach and in those treated with the gold standard approach in district&#xD;
      hospitals.&#xD;
&#xD;
      Secondary objectives: To compare between the two approaches the virologic effectiveness,&#xD;
      survival, treatment interruptions, number of patients lost to follow-up, clinical&#xD;
      progression, clinical and biologic tolerability, adherence, emergence of drug resistances,&#xD;
      impact on patients' daily life, acceptability by the patients and health professionals, and&#xD;
      cost-effectiveness performances.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      Randomised, controlled, multicentre, non inferiority, intervention trial, without blind for&#xD;
      approach, in 9 district hospitals of the Province du Centre in Cameroon. 430 adult patients&#xD;
      will be randomised in two groups (&quot;simplified&quot; approach or gold standard approach) with a 1:1&#xD;
      ratio and followed for 24 months.&#xD;
&#xD;
      In the &quot;simplified&quot; approach, the results of the HIV-1 viral load and CD4 cell count will not&#xD;
      be available for the management of patients, the biologic assessment of tolerability will be&#xD;
      limited and some clinical consultations will be performed by nurses under the physicians'&#xD;
      responsibility; the remainder will be similar to the gold standard approach.&#xD;
&#xD;
      Planning&#xD;
&#xD;
      The study will start in the first semester of 2006. The full length of the study would be 36&#xD;
      months maximum (12 months for enrolment and 24 months for follow-up).&#xD;
&#xD;
      Expected results&#xD;
&#xD;
      Advices for increasing access to ART in Africa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in the CD4 cell count measured with a FACSCount apparatus after 24 months of antiretroviral therapy</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with viral load below 400 copies/ml and 50 copies/ml, respectively (Abbott RealTime HIV-1)</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival probability</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of treatment interruption</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of patients lost to follow-up</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical events (WHO stage III or IV)</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adherence</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with drug resistance</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability by the patients and health professionals of both approaches</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on patients' daily life</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness ratio</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simplify treatment follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Simplified follow-up approach of ARV treatment</intervention_name>
    <description>Simplify treatment follow-up :&#xD;
some clinical consultations will be performed by nurses under the physicians' responsibility ;&#xD;
the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;&#xD;
the biologic assessment for tolerability will be limited</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard follow-up approach of ARV treatment</intervention_name>
    <description>Standard treatment follow-up :&#xD;
all clinical consultations will be performed by physicians ;&#xD;
the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;&#xD;
the biologic assessment for tolerability will be available as needed</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged at least 18 years&#xD;
&#xD;
          -  Living in the health district of the hospital attended&#xD;
&#xD;
          -  Confirmed HIV-1 group M infection&#xD;
&#xD;
          -  Meeting one of the following criteria:&#xD;
&#xD;
               -  Stage III or IV (WHO classification)&#xD;
&#xD;
               -  Stage II (WHO classification) and total lymphocytes count ≤ 1200/mm3&#xD;
&#xD;
          -  Patient agreeing on monthly follow-up and treatment for 24 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-1 group O or N, or HIV-2 infection&#xD;
&#xD;
          -  HIV-1 primary infection&#xD;
&#xD;
          -  Progressive tuberculosis in treatment and total lymphocytes count &gt; 1200/mm3&#xD;
&#xD;
          -  Progressive tumor or malignant lymphoma (except cutaneous or mucous Kaposi sarcoma)&#xD;
&#xD;
          -  Progressive psychiatric disorder&#xD;
&#xD;
          -  Hepatocellular disorder&#xD;
&#xD;
          -  History of antiretroviral therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Laurent</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Delaporte</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sinata Koulla-Shiro</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Central, Yaoundé, Cameroun</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Kouandack</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Central, Yaoundé, Cameroun</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de district d'Ayos</name>
      <address>
        <city>Ayos</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Bafia</name>
      <address>
        <city>Bafia</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Mfou</name>
      <address>
        <city>Mfou</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Monatélé</name>
      <address>
        <city>Monatélé</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Nanga Eboko</name>
      <address>
        <city>Naga Eboko</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Ndikiniméki</name>
      <address>
        <city>Ndikiniméki</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district d'Obala</name>
      <address>
        <city>Obala</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Sa'a</name>
      <address>
        <city>Sa'a</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de district de Mbalmayo</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 10, 2006</study_first_submitted>
  <study_first_submitted_qc>March 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiretroviral treatment</keyword>
  <keyword>Expanded access</keyword>
  <keyword>Africa</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

